• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌合并胆管癌的切除与移植治疗比较

Comparison between resection and transplantation in combined hepatocellular and cholangiocarcinoma.

作者信息

Song S, Moon H H, Lee S, Kim T-S, Shin M, Kim J M, Park J B, Kwon C H D, Kim S J, Lee S-K, Joh J-W

机构信息

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Transplant Proc. 2013 Oct;45(8):3041-6. doi: 10.1016/j.transproceed.2013.08.064.

DOI:10.1016/j.transproceed.2013.08.064
PMID:24157032
Abstract

OBJECTIVE

The treatment of choice for combined hepatocellular and cholangiocarcinoma (cHCC-CC) is surgical resection. However, the efficacy of liver transplantation is not clear. We compared the surgical outcome of hepatic resection and liver transplantation for cHCC-CC.

PATIENTS AND METHODS

From 1995 to 2012, 89 patients were diagnosed with cHCC-CC after hepatic resection and 8 patients diagnosed with cHCC-CC after liver transplantation. We excluded 21 patients who were American Joint Committee on Cancer Staging Stage III or IV and lost to follow-up. The outcomes were reviewed retrospectively.

RESULTS

The poor prognostic factors in cHCC-CC patients who underwent hepatectomy were large tumor size (>5 cm), small safety margin (<2 cm), and low preoperative albumin level. The disease-free survival (DFS) and overall survival (OS) between the hepatectomy group (n = 68) and the liver transplant group (n = 8) was not statistically different (5-year DFS: 26.2% vs 37.5%, P = .333; 5-year OS: 42.1% vs 50%, P = .591). In the small tumor subgroup (tumor size <5 cm), the DFS and OS between the 2 surgical procedures was not different, and in the adequate resection margin subgroup (safety margin >2 cm), survival was comparable.

CONCLUSIONS

In well-selected cases with small tumor size and with preserved liver function, liver resection should be considered when complete resection is possible.

摘要

目的

肝细胞癌合并胆管癌(cHCC-CC)的首选治疗方法是手术切除。然而,肝移植的疗效尚不清楚。我们比较了cHCC-CC肝切除和肝移植的手术结果。

患者与方法

1995年至2012年,89例患者在肝切除术后被诊断为cHCC-CC,8例患者在肝移植术后被诊断为cHCC-CC。我们排除了21例美国癌症联合委员会分期为III期或IV期且失访的患者。对结果进行回顾性分析。

结果

接受肝切除术的cHCC-CC患者的不良预后因素为肿瘤体积大(>5 cm)、安全切缘小(<2 cm)和术前白蛋白水平低。肝切除组(n = 68)和肝移植组(n = 8)之间的无病生存期(DFS)和总生存期(OS)无统计学差异(5年DFS:26.2%对37.5%,P = 0.333;5年OS:42.1%对50%,P = 0.591)。在小肿瘤亚组(肿瘤大小<5 cm)中,两种手术方式的DFS和OS无差异,在切缘足够的亚组(安全切缘>2 cm)中,生存率相当。

结论

在精心挑选的肿瘤体积小且肝功能良好的病例中,如果有可能完全切除,应考虑肝切除。

相似文献

1
Comparison between resection and transplantation in combined hepatocellular and cholangiocarcinoma.肝细胞癌合并胆管癌的切除与移植治疗比较
Transplant Proc. 2013 Oct;45(8):3041-6. doi: 10.1016/j.transproceed.2013.08.064.
2
Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma.肝细胞-胆管癌合并症的特征及与肝内胆管癌的比较。
Eur J Surg Oncol. 2014 Aug;40(8):976-81. doi: 10.1016/j.ejso.2014.04.016. Epub 2014 May 23.
3
Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma.肝癌合并胆管细胞癌患者的肝移植与切除术比较。
J Surg Oncol. 2013 May;107(6):608-12. doi: 10.1002/jso.23289. Epub 2013 Feb 5.
4
Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.肝移植和切除术后肝细胞癌-胆管癌合并症的长期预后
Liver Transpl. 2017 Mar;23(3):330-341. doi: 10.1002/lt.24711.
5
Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.临床病理因素影响肝癌合并胆管细胞癌切除术后的生存结局。
Surg Oncol. 2013 Mar;22(1):55-60. doi: 10.1016/j.suronc.2012.09.003. Epub 2012 Oct 24.
6
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌:临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
7
Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.肝细胞-胆管细胞癌:一种罕见原发性肝癌的人群水平分析
Liver Transpl. 2014 Aug;20(8):952-9. doi: 10.1002/lt.23897. Epub 2014 Jul 3.
8
Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.肝移植患者中的肝内胆管细胞癌或混合性肝细胞-胆管细胞癌:一项西班牙匹配队列多中心研究。
Ann Surg. 2014 May;259(5):944-52. doi: 10.1097/SLA.0000000000000494.
9
Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma.肝硬化对肝细胞胆管癌合并症患者术后长期预后的影响。
BMC Gastroenterol. 2017 Feb 10;17(1):25. doi: 10.1186/s12876-017-0584-y.
10
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.15例肝细胞癌合并胆管癌患者的临床病理特征
Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5.

引用本文的文献

1
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.病例报告:酪氨酸激酶抑制剂对肝细胞-胆管癌联合治疗的持久反应。
Front Oncol. 2025 Mar 18;15:1459705. doi: 10.3389/fonc.2025.1459705. eCollection 2025.
2
Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor.肝细胞癌合并胆管癌中的肉瘤样改变作为一个预后不良因素。
J Gastrointest Oncol. 2024 Aug 31;15(4):1796-1804. doi: 10.21037/jgo-24-313. Epub 2024 Aug 22.
3
An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma.
肝细胞胆管癌联合治疗策略的国际多中心评估
JHEP Rep. 2023 Mar 28;5(6):100745. doi: 10.1016/j.jhepr.2023.100745. eCollection 2023 Jun.
4
Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center.混合型肝细胞胆管癌:单中心混合型肿瘤、肝内胆管癌与肝细胞癌生存情况比较
Cancers (Basel). 2023 Jan 19;15(3):639. doi: 10.3390/cancers15030639.
5
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.肝细胞癌-胆管癌合并症的病理学:最新进展
Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494.
6
Contrast-enhanced ultrasound manifestations of synchronous combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma: A case report.同步性肝细胞胆管癌与肝细胞癌的超声造影表现:一例报告
World J Clin Cases. 2022 Apr 16;10(11):3615-3623. doi: 10.12998/wjcc.v10.i11.3615.
7
Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.肝移植在肝细胞胆管癌合并患者中的潜在作用:一项倾向评分匹配分析
Ann Transl Med. 2022 Apr;10(8):434. doi: 10.21037/atm-21-5391.
8
Living donor liver transplantation for intra hepatic cholangiocarcinoma.活体供肝肝移植治疗肝内胆管癌
Ann Med Surg (Lond). 2020 Jul 21;57:82-84. doi: 10.1016/j.amsu.2020.07.028. eCollection 2020 Sep.
9
Treatment of Combined Hepatocellular and Cholangiocarcinoma.肝细胞癌合并胆管癌的治疗
Cancers (Basel). 2020 Mar 26;12(4):794. doi: 10.3390/cancers12040794.
10
Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions.肝内胆管癌合并肝细胞癌(cHCC-CC):遗传学、分子生物学及治疗干预的最新进展
J Hepatocell Carcinoma. 2018 Dec 28;6:11-21. doi: 10.2147/JHC.S159805. eCollection 2019.